Establishment of a new Glivec-resistant chronic myeloid leukemia cell line, SNUCML-02, using an in vivo model

Experimental Hematology

Volumn 38, Issue 9, 2010, Pages 773-781

  Park, Juwon ^a   Kim, Kyung Im ^b   Koh, Youngil ^c   Won, Nam Hee ^d   Oh, Jung Mi ^b   Lee, Dong Soon ^e   Kim, Byoung Kook ^a,c   Ahn, Kwang Sung ^d   Yoon, Sung Soo ^a,c,f  

^a Cancer Research Institute   (South Korea)

^b Seoul National University   (South Korea)

^c Seoul National University College of Medicine   (South Korea)

^d Korea University College of Medicine   (South Korea)

^e Seoul National University Hospital   (South Korea)

^f Seoul National University Hospital   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ABELSON KINASE; BCR ABL PROTEIN; IMATINIB; INTERLEUKIN 3; MITOGEN ACTIVATED PROTEIN KINASE;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANOREXIA; ARTICLE; BONE MARROW CELL; CANCER RESISTANCE; CASE REPORT; CELL PROLIFERATION; CELL STRAIN; CELL STRAIN SNUCML 02; CHROMOSOME G BAND; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CYTOGENETICS; DISEASE COURSE; DRUG EFFICACY; ENZYME ACTIVATION; EX VIVO STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE MUTATION; HUMAN; HUMAN CELL; HYPOXEMIA; LEUKEMIA CELL LINE; LEUKOCYTE COUNT; MONONUCLEAR CELL; NAUSEA; NONHUMAN; NUCLEOTIDE SEQUENCE; PNEUMONIA; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; WEAKNESS; WESTERN BLOTTING;

BOVINAE; MUS;

EID: 77955517291     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2010.04.012     Document Type: Article

References (14)

1. Sawyers C.L. Chronic myeloid leukemia. N Engl J Med 1999, 340:1330-1340.
2. Faderl S., Talpaz M., Estrov Z., O'Brien S., Kurzrock R., Kantarjian H.M. The biology of chronic myeloid leukemia. N Engl J Med 1999, 341:164-172.
3. Ren R. Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat Rev Cancer 2005, 5:172-183.
4. Laurent E., Talpaz M., Kantarjian H., Kurzrock R. The BCR gene and Philadelphia chromosome-positive leukemogenesis. Cancer Res 2001, 61:2343-2355.
5. Druker B.J. Inhibition of the Bcr-Abl tyrosine kinase as a therapeutic strategy for CML. Oncogene 2002, 21:8541-8546.
6. Buchdunger E., Matter A., Druker B.J. Bcr-Abl inhibition as a modality of CML therapeutics. Biochim Biophys Acta 2001, 1551:M11-M18.
7. Thiesing J.T., Ohno-Jones S., Kolibaba K.S., Druker B.J. Efficacy of STI571, an abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against bcr-abl-positive cells. Blood 2000, 96:3195-3199.
8. Gorre M.E., Sawyers C.L. Molecular mechanisms of resistance to STI571 in chronic myeloid leukemia. Curr Opin Hematol 2002, 9:303-307.
9. Branford S., Rudzki Z., Walsh S., et al. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood 2003, 102:276-283.
10. Hochhaus A., Kreil S., Corbin A.S., et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 2002, 16:2190-2196.
11. Campbell L.J., Patsouris C., Rayeroux K.C., Somana K., Januszewicz E.H., Szer J. BCR/ABL amplification in chronic myelocytic leukemia blast crisis following imatinib mesylate administration. Cancer Genet Cytogenet 2002, 139:30-33.
12. Donato N.J., Wu J.Y., Stapley J., et al. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 2003, 101:690-698.
13. Donato N.J., Wu J.Y., Stapley J., et al. Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia. Cancer Res 2004, 64:672-677.
14. Dorsey J.F., Cunnick J.M., Lanehart R., et al. Interleukin-3 protects Bcr-Abl transformed hematopoietic progenitor cells from apoptosis induced by Bcr-Abl tyrosine kinase inhibitors. Leukemia 2002, 16:1589-1595.